ETS transcription factors: Oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer

Expert Review of Anticancer Therapy

Volumn 8, Issue 1, 2008, Pages 33-42

  Turner, David P ^a   Watson, Dennis K ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

ETS factor; Gene fusion; Metastasis; Oncogene; Prostate cancer; Therapeutic target; Transcription; Tumor suppressor

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTISENSE OLIGODEOXYNUCLEOTIDE; BEVACIZUMAB; CETUXIMAB; CYCLOSPORIN A; IMATINIB; MONOCLONAL ANTIBODY; OLIGODEOXYNUCLEOTIDE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PEPTIDE NUCLEIC ACID; SALICYLIC ACID; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TAMOXIFEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ELF 1; TRANSCRIPTION FACTOR ER81; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR ETS 2; TRANSCRIPTION FACTOR ETV4; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR FLI 1; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER GENE THERAPY; CANCER GROWTH; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DIAGNOSTIC VALUE; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GENE TARGETING; GENE TECHNOLOGY; HUMAN; NONHUMAN; ONCOGENE; PROGNOSIS; PROMOTER REGION; PROSTATE CANCER; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; GENE THERAPY; GENETICS; MALE; PROSTATE TUMOR;

GENE THERAPY; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; ONCOGENES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ETS;

EID: 38349047019     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.1.33     Document Type: Review

References (55)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J. Clin. 57(1), 43-66 (2007).
2. Seth A, Watson DK. ETS transcription factors and their emerging roles in human cancer. Eur. J. Cancer 41(16), 2462-2478 (2005).
3. Turner DP, Findlay VJ, Moussa O, Watson DK. Defining ETS transcription regulatory networks and their contribution to breast cancer progression. J. Cell. Biochem. 102(3), 549-559 (2007).
4. Tomlins SA, Mehra R, Rhodes DR et al. Integrative molecular concept modeling of prostate cancer progression. Nat. Genet. 39(1), 41-51 (2007).
5. Hollenhorst PC, Jones DA, Graves BJ. Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. Nucleic Acids Res. 32(18), 5693-5702 (2004).
6. Park C, Lee I, Kang WK. Influence of small interfering RNA corresponding to ETS homologous factor on senescence-associated modulation of prostate carcinogenesis. Mol. Cancer Ther. 5(12), 3191-3196 (2006).
7. Tugores A, Le J, Sorokina I et al. The epithelium-specific ETS protein EHF/ESE-3 is a context-dependent transcriptional repressor downstream of MAPK signaling cascades. J. Biol. Chem. 276(23), 20397-20406 (2001).
8. Alipov G, Nakayama T, Ito M et al. Overexpression of Ets-1 proto-oncogene in latent and clinical prostatic carcinomas. Histopathology 46(2), 202-208 (2005).
9. Liu AY, Corey E, Vessella RL et al. Identification of differentially expressed prostate genes: increased expression of transcription factor ETS-2 in prostate cancer. Prostate 30(3), 145-153 (1997).
10. Petrovics G, Liu A, Shaheduzzaman S et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24(23), 3847-3852 (2005).
11. Soller MJ, Isaksson M, Elfving P et al. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosome Cancer 45(7), 717-719 (2006).
12. Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748), 644-648 (2005).
13. Tomlins SA, Mehra R, Rhodes DR et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 66(7), 3396-3400 (2006).
14. Perner S, Demichelis F, Beroukhim R et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 66(17), 8337-8341 (2006).
15. Clark J, Merson S. Jhavar S et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 26(18), 2667-2673 (2007).
16. Cerveira N, Ribeiro FR, Peixoto A et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 8(10), 826-832 (2006).
17. Mosquera JM, Perner S, Demichelis F et al. Morphological features of TMPRSS2-ERG gene fusion prostate cancer. J. Pathol. 212(1), 91-101 (2007).
18. Nozawa M, Yomogida K, Kanno N et al. Prostate-specific transcription factor hPSE is translated only in normal prostate epithelial cells. Cancer Res. 60(5), 1348-1352 (2000).
19. Feldman RJ, Sementchenko VI, Gayed M, Fraig MM, Watson DK. Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res. 63(15), 4626-4631 (2003).
20. Gu X, Zerbini LF, Otu HH et al. Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells. Cancer Res. 67(9), 4219-4226 (2007).
21. Turner DP, Moussa O, Sauane M, Fisher PB, Watson DK. Prostate-derived ETS factor is a mediator of metastatic potential through the inhibition of migration and invasion in breast cancer. Cancer Res. 67(4), 1618-1625 (2007).
22. Kibel AS, Freije D, Isaacs WB, Bova GS. Deletion mapping at 12p12-13 in metastatic prostate cancer. Genes Chromosome Cancer 25(3), 270-276 (1999).
23. Laxman B, Tomlins SA, Mehra R et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 8(10), 885-888 (2006).
24. Iljin K, Wolf M. Edgren H et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res. 66(21), 10242-10246 (2006).
25. Attard G, Clark J, Ambroisine L et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene (2007) (In Press).
26. Karamouzis MV, Gorgoulis VG, Papavassiliou AG. Transcription factors and neoplasia: vistas in novel drug design. Clin. Res. 8(5), 949-961 (2002).
27. Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat. Rev. Drug Discov. 2(3), 205-213 (2003).
28. Sahin A, Velten M, Pietsch T et al. Inactivation of ETS 1 transcription factor by a specific decoy strategy reduces rat C6 glioma cell proliferation and MMP-9 expression. Int. J. Mol. Med. 15(5), 771-776 (2005).
29. Miwa K, Nakashima H, Aoki M et al. Inhibition of ets, an essential transcription factor for angiogenesis, to prevent the development of abdominal aortic aneurysm in a rat model. Gene Ther. 12(14), 1109-1118 (2005).
30. Iwasaka C, Tanaka K, Abe M, Sato Y. ETS-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells. J. Cell Physiol. 169(3), 522-531 (1996).
31. Corradini R, Sforza S, Tedeschi T, Totsingan F, Marchelli R. Peptide nucleic acids with a structurally biased backbone: effects of conformational constraints and stereochemistry. Curr. Top. Med. Chem. 7(7), 681-694 (2007).
32. Besch R, Giovannangeli C, Degitz K. Triplex-forming oligonucleotides - sequence-specific DNA ligands as tools for gene inhibition and for modulation of DNA-associated functions. Curr. Drug Targets 5(8), 691-703 (2004).
33. Carbone GM, McGuffie EM, Collier A, Catapano CV. Selective inhibition of transcription of the ETS2 gene in prostate cancer cells by a triplex-forming oligonucleotide. Nucleic Acids Res. 31(3), 833-843 (2003).
34. Carbone GM, Napoli S, Valentini A et al. Triplex DNA-mediated downregulation of ETS2 expression results in growth inhibition and apoptosis in human prostate cancer cells. Nucleic Acids Res. 32(14), 4358-4367 (2004).
35. Vasquez KM, Narayanan L, Glazer PM. Specific mutations induced by triplex-forming oligonucleotides in mice. Science 290(5491), 530-533 (2000).
36. Kitange G, Shibata S, Tokunaga Y et al. ETS-1 transcription factor-mediated urokinase-type plasminogen activator expression and invasion in glioma cells stimulated by serum and basic fibroblast growth factors. Lab. Invest. 79(4), 407-416 (1999).
37. Wernert N, Stanjek A, Kiriakidis S et al. Inhibition of angiogenesis in vivo by ETS-1 antisense oligonucleotides-inhibition of Ets-2 transcription factor expression by the antibiotic fumagillin. Angew. Chem. Int. Ed. Engl. 38(21), 3228-3231 (1999).
38. Dorsett Y, Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nat. Rev. Drug Discov. 3(4), 318-329 (2004).
39. Cai C, Hsieh CL, Omwancha J et al. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol. Endocrinol. 21(8), 1835-1846 (2007).
40. Tomlins SA, Laxman B, Dhanasekaran SM et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448(7153), 595-599 (2007).
41. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 431(7006), 371-378 (2004).
42. Dohjima T, Lee NS, Li H, Ohno T, Rossi JJ. Small interfering RNAs expressed from a Pol III promoter suppress the EWS/Fli-1 transcript in an Ewing sarcoma cell line. Mol. Ther. 7(6), 811-816 (2003).
43. Hu-Lieskovan S. Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65(19), 8984-8992 (2005).
44. Stegmaier K, Wong JS, Ross KN et al. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med. 4(4), E122 (2007).
45. Yamashita M. Recent advances in the generation of human monoclonal antibody. Cytotechnology 55, 55-60 (2007).
46. Milowsky MI, Nanus DM, Kostakoglu L et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J. Clin. Oncol. 22(13), 2522-2531 (2004).
47. Milowsky MI, Nanus DM, Kostakoglu L et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J. Clin. Oncol. 25(5), 540-547 (2007).
48. Foos G, Hauser CA. Altered ETS transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness. Oncogene 19(48), 5507-5516 (2000).
49. Sementchenko VI, Schweinfest CW, Papas TS, Watson DK. ETS2 function is required to maintain the transformed state of human prostate cancer cells. Oncogene 17(22), 2883-2888 (1998).
50. Pourtier-Manzanedo A, Vercamer C, Van Belle E et al. Expression of an Ets-1 dominant-negative mutant perturbs normal and tumor angiogenesis in a mouse ear model. Oncogene 22(12), 1795-1806 (2003).
51. Hewett PW, Daft EL, Laughton CA et al. Selective inhibition of the human tie-1 promoter with triplex-forming oligonucleotides targeted to ETS binding sites. Mol. Med. 12(1-3) 8-16 (2006).
52. Shimogawa H, Kwon Y, Mao Q et al. A wrench-shaped synthetic molecule that modulates a transcription factor - coactivator interaction. J. Am. Chem. Soc. 126(11), 3461-3471 (2004).
53. Jung D, Choi Y, Uesugi M. Small organic molecules that modulate gene transcription. Drug Discov. Today, 11(9-10), 452-457 (2006).
54. McCormick F. Cancer gene therapy: fringe or cutting edge? Nat. Rev. Cancer 1(2), 130-141 (2001).
55. Marx J. Recruiting the cells own guardians for cancer therapy. Science 315(5816), 1211-1213 (2007).